CEO Executive AssistantPatient safety reporting is one of the most regulated and consequential functions in the pharmaceutical industry. Adverse event collection, assessment, and reporting to regulatory agencies are legal obligations with specific timelines, format requirements, and quality standards. The pharmacovigilance function that manages these obligations requires specialized expertise in safety science, regulatory requirements, and case management.
For a pharma CEO, safety reporting presents a distinctive delegation challenge: the consequences of failure are patient safety-related and regulatory, but the function is so operationally complex and regulatory-specific that CEO involvement in execution adds no value and creates unnecessary risk of confusion. The appropriate delegation system puts safety reporting firmly in the hands of pharmacovigilance professionals while maintaining CEO-level oversight through structured reporting and escalation protocols.
The Safety Function Leadership Structure
The Head of Pharmacovigilance or VP of Drug Safety is the CEO’s primary delegate for the safety reporting function. This person must have specialized training in pharmacovigilance, strong understanding of global safety reporting requirements (FDA 21 CFR 312.32, EMA regulations, ICH E2A/E2B guidelines), and the organizational authority to make safety reporting decisions without commercial influence.
The organizational reporting structure for the safety function matters. Pharmacovigilance should report through the CMO or directly to the CEO, not through the commercial organization or a COO with primarily operational responsibilities. The independence of the safety function from commercial pressure is a regulatory expectation and a patient safety requirement.
The CEO’s safety function relationship involves: ensuring the function is adequately resourced, receiving the structured safety reporting described below, and being the escalation point for any safety developments with strategic implications.
Defining the Pharmacovigilance Delegation Scope
All pharmacovigilance operational activities should be fully delegated to the safety function:
Individual Case Safety Reports (ICSRs): Collection, medical assessment, narrative writing, and regulatory submission of all adverse event reports from clinical trials, spontaneous reports, literature, and other sources. This is entirely a pharmacovigilance function operation.
Expedited Safety Reporting: The 7-day and 15-day reporting requirements for serious unexpected adverse drug reactions and suspected unexpected serious adverse reactions (SUSARs) in clinical trials. These are time-critical operations managed by the safety function against regulatory timelines, not by the CEO.
Periodic Safety Reports: The Periodic Benefit-Risk Evaluation Reports (PBRERs), Periodic Safety Update Reports (PSURs), and Development Safety Update Reports (DSURs) that provide regulatory agencies with cumulative safety information. These are complex documents managed by the safety function.
Safety Signal Detection and Assessment: The ongoing analysis of safety data from all sources to detect potential signals of unexpected adverse events. The safety function runs the signal detection program and conducts formal signal assessments.
Risk Management Plans: For products with identified safety risks, the development and implementation of risk minimization measures required by regulatory agencies.
None of these activities require CEO involvement. They require qualified pharmacovigilance professionals with appropriate systems and expertise.
CEO-Level Safety Reporting: What Reaches the Executive Level
The CEO does not need to see every adverse event report, but they do need to know about safety developments that have strategic, regulatory, or reputational implications. The delegation system defines this through structured reporting and escalation triggers.
Weekly safety summary: A brief written update from the Head of Pharmacovigilance covering: total SAEs reported in the prior week across all programs, any expedited regulatory reports submitted (without individual patient detail), any significant safety developments in clinical programs, and any safety-related regulatory correspondence received or sent.
Monthly safety dashboard: A structured summary covering: SAE volume by seriousness category, reporting compliance metrics (percentage of reports submitted on time), current signal status for each marketed product and clinical program, and any significant findings from the DSMB for ongoing trials.
Immediate escalation triggers: The Head of Pharmacovigilance immediately contacts the CEO for: a new or evolving safety signal that could affect the benefit-risk assessment of a marketed product or clinical program, a clinical hold imposed by a regulatory agency for safety reasons, a serious labeled adverse event occurring at an unexpected frequency, any safety issue that may require public communication, and any safety matter that will be reviewed by an upcoming DSMB meeting with potential program implications.
This structure ensures the CEO is informed about safety at a strategic level while the safety function manages all operational safety activities.
Pharmacovigilance Systems Delegation
Pharmacovigilance systems, including safety databases (such as Argus or ARIS-G), signal detection tools, and reporting automation, are operational infrastructure that the safety function owns and manages. The CEO’s involvement in pharmacovigilance systems is limited to: approving significant system investments or replacements as capital budget decisions, and receiving any system-related compliance concerns through the standard escalation protocol.
The Head of Pharmacovigilance and the IT function jointly manage pharmacovigilance system operations and maintenance. System validation, upgrade management, and integration with clinical data systems are technical functions that the CEO should not be involved in managing.
Clinical Trial Safety Oversight Delegation
In clinical trials, safety oversight involves multiple interconnected systems: the investigator site safety monitoring, the sponsor pharmacovigilance function, and the independent Data Safety Monitoring Board (DSMB). The CEO’s relationship to clinical trial safety oversight should be mediated through the CMO and the Head of Pharmacovigilance.
The CEO should understand: which trials have DSMBs, the frequency of DSMB reviews, and the DSMB charter’s stopping rules. The CEO should receive DSMB action letters (the documents the DSMB provides after each review) through the CMO/safety function reporting channel, not independently from the DSMB.
When a DSMB recommends holding or stopping a trial for safety reasons, this is an immediate CEO escalation. The CMO and Head of Pharmacovigilance present the DSMB recommendation, the safety data, and a recommended organizational response. The CEO makes the decision on program continuation with the benefit of this expert input.
For context on how clinical trial safety oversight connects to the broader clinical operations delegation structure, see pharma CEO clinical ops, which provides a comprehensive framework for delegating clinical operations while maintaining appropriate safety oversight.
Post-Marketing Safety Surveillance Delegation
For marketed products, ongoing post-marketing safety surveillance is a regulatory requirement and a patient safety imperative. The safety function owns: spontaneous adverse event collection from healthcare providers and patients, post-marketing study safety monitoring, literature surveillance, and regulatory signal assessments.
Post-marketing safety surveillance results feed into the periodic safety reports (PBRERs/PSURs) that the safety function prepares. The CEO reviews these reports at the summary level, through the monthly safety dashboard, rather than reviewing each periodic report in detail.
If a post-marketing safety signal reaches the threshold that requires regulatory communication (such as a label update or a Dear Healthcare Provider letter), this is a CEO escalation and, depending on the significance of the label change, potentially a board notification. The Head of Pharmacovigilance and the CMO initiate the escalation; the CEO approves the regulatory communication strategy.
Pharmacovigilance Quality and Compliance Delegation
Pharmacovigilance operations are subject to regulatory inspection and must comply with specific quality standards. Pharmacovigilance quality, including the SOPs that govern case handling, the training program for pharmacovigilance staff, internal audits of pharmacovigilance processes, and inspection readiness, should be owned by the Quality function in coordination with the Head of Pharmacovigilance.
The CEO should receive a quarterly pharmacovigilance compliance summary that covers: audit findings from pharmacovigilance processes, CAPA status for any open pharmacovigilance quality issues, and any regulatory agency feedback on pharmacovigilance submissions.
For significant pharmacovigilance inspection findings or regulatory enforcement actions, the CEO is immediately notified through the escalation protocol.
According to McKinsey analysis of pharmaceutical safety governance, pharmaceutical companies that invest in strong pharmacovigilance capabilities with clear governance structures significantly reduce their regulatory risk and build more sustainable commercial positions. The delegation system above is designed to enable this investment while maintaining appropriate CEO oversight.
Board Safety Reporting
The board should receive an annual safety report from the CMO and Head of Pharmacovigilance covering: the company’s safety profile for marketed products, significant safety events from the year, pharmacovigilance program performance, and the company’s proactive safety monitoring capabilities.
The CEO participates in this board presentation but the safety content is presented by the safety experts. This positions the safety function as a direct board resource and ensures the board has genuine insight into safety governance rather than a CEO-summarized overview.
See pharma CEO delegation guide for a comprehensive view of how the safety reporting delegation system connects to the full range of pharma CEO regulatory and quality governance responsibilities.
Implementing the Safety Reporting Delegation System
For CEOs who are currently more operationally involved in safety reporting than this system prescribes, the transition requires deliberate steps:
First, assess whether the Head of Pharmacovigilance has the expertise and organizational authority to own the function. If not, this is the first investment to make.
Second, establish the reporting cadence described above: weekly brief, monthly dashboard, immediate escalation protocol. These structural elements give the CEO reliable visibility without operational involvement.
Third, commit to using the escalation protocol rather than ad hoc safety inquiries. CEOs who send frequent ad hoc requests for safety data signal distrust and create compliance risk through informal data channels.
Fourth, review annually whether the escalation triggers are calibrated correctly. As the portfolio and safety profile evolve, the triggers may need updating.
The result of this investment is a safety reporting delegation system that protects patients, satisfies regulators, and allows the CEO to exercise genuine oversight of one of the industry’s most consequential functions without consuming executive time on operational pharmacovigilance management.
Related Reading
For further context, explore Delegation System for Automotive CEO: Compliance Team and Delegation System for Automotive CEO: Engineering Teams.